BAY 604552

Drug Profile

BAY 604552

Alternative Names: BAY-604552; BAY98-7081; sGC activator - Bayer

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Bayer HealthCare
  • Class Heart failure therapies
  • Mechanism of Action Guanylate cyclase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Erectile dysfunction; Heart failure

Most Recent Events

  • 31 May 2011 Bayer completes a phase II trial in Erectile Dysfunction in Finland, France, Germany, Italy, Netherlands, Spain and Sweden (NCT01168817)
  • 24 Mar 2011 Bayer Healthcare completes enrolment in its phase II trial for Erectile dysfunction in Europe (NCT01168817)
  • 23 Aug 2010 Phase-II clinical trials in Erectile dysfunction in Finland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top